Oil prices have recently spiked on concerns around the Strait of Hormuz, which keeps inflation risks on the radar for central banks and keeps borrowing conditions in focus for listed companies. Founder led businesses often react faster when conditions change, because leadership has more skin in the game. This article highlights three founder led stocks from the screener that show how this mindset can matter for long term investors.

The three stocks below are just a small sample from the founder led group, and the full screen surfaced 1,455 more companies with equally compelling stories that are not covered here. To go deeper into this idea, identify candidates that fit your style and analyze them on the Founder-Led Companies screener.

GigaCloud Technology (GCT)

GigaCloud Technology runs a B2B ecommerce marketplace that connects Asian manufacturers with resellers in the US, Europe and Asia for bulky items like furniture, appliances and fitness equipment, and wraps in payments and logistics on a single platform. The business currently reports all its revenue from wholesale miscellaneous products, at about $1.47b, and has a market cap of roughly $1.9b, which puts it firmly in mid cap territory.

Investors scanning for founder led growth stories may find GigaCloud Technology interesting because it combines fast scaling cross border ecommerce with solid fundamentals, including a net profit margin around 10.6% and high ROE of 29.2%. The company is debt free and has been using buybacks funded from cash, including a new three year $120 million program. At the same time, Europe driven growth and acquisitions like New Classic point to an ambition to build a larger platform over time. The flip side is that the story leans heavily on Europe and on smooth global trade, so tariff shifts, supply chain snags or weaker service revenue could quickly test that margin profile and the current valuation thesis.

GigaCloud Technology’s mix of high ROE, cash funded buybacks and cross border ecommerce scale can look like a rare combination. Before assuming the story is straightforward, review the analysis report for GigaCloud Technology.

Build your own high ROE ecommerce shortlist

GigaCloud Technology and the two other founder led stocks here all surfaced from a single Simply Wall St screen, but the real edge is in building filters that fit your own process. Use our flexible Screener to combine metrics like valuation, quality and risks into your own watchlist, or start from any of our curated Investing Ideas.

ACM Research (ACMR)

ACM Research develops and sells equipment used in semiconductor manufacturing, from wet cleaning tools to advanced electroplating and packaging systems, serving chip fabs and packaging plants in China and internationally. The company has a market cap of about US$5.8b, which places it in mid to large cap territory.

ACM Research is exposed to rising demand for more complex chips used in AI and advanced computing, with strong recent earnings, growing contributions from higher value plating and packaging tools, and analyst forecasts pointing to solid revenue and profit growth. At the same time, almost all of the big goals for 2029 depend on continued strength in China’s wafer fab spending and on managing export control risk, while high R&D and rising borrowings keep financial discipline in focus. For investors who can handle volatility, this mix of growth exposure and concentration risk may warrant closer consideration.

ACM Research sits at the crossroads of AI chip demand and China focused risk, and the real story only shows up when you line those together with the analyst forecasts for ACM Research that could reveal what the market might be missing.

Doximity (DOCS)

Doximity runs a US based digital platform for medical professionals, combining a personalized medical newsfeed with tools like AI assisted clinical search, documentation and telehealth. The company generates all of its roughly $656 million in revenue from healthcare software, primarily serving physicians, advanced practice clinicians, students, pharma companies and health systems. With a market cap near $4.9b, Doximity sits firmly in the mid cap bracket.

Investors watching founder led healthcare tech may find Doximity interesting because it blends a highly engaged clinician network with fast growing AI tools like Scribe and AI Search that could deepen its role inside hospital workflows and pharma marketing budgets. The stock trades below some fair value estimates and sits on a 25.5% net margin, yet still carries real questions around heavy near term AI spend, reliance on pharma advertising and a relatively new management team. Recent analyst moves, from upbeat AI driven target hikes to Wells Fargo’s downgrade, underline how much hinges on whether this AI investment year converts into durable earnings growth and stronger returns on capital.

Doximity’s AI tools look like they could be rewiring how clinicians work and how pharma spends, yet the real inflection might sit inside the analyst forecasts for Doximity that hints at a very different earnings mix ahead.

Seeking Fresh Alternatives Before They Fly

Fresh ideas often move first and move fast. Before the next breakout gathers momentum and gets caught by the crowd, scan these under the radar lists while it matters and act now.

• Spot cash generative outliers early by running the 51 high quality undervalued stocks that filters for quality businesses where balance sheets and earnings power still look underappreciated by the wider market.
• Track where AI adoption meets real profitability by checking the curated 71 profitable AI stocks that aren't just burning cash that highlights companies building momentum without relying purely on cash burn and promises.
• Position ahead of the energy transition by reviewing the focused 89 nuclear energy infrastructure stocks that zeroes in on infrastructure players tied to potential long term nuclear build outs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.